Please try another search
For the nine months ended 30 September 2019, Audentes Therapeutics Inc revenues was not reported. Net loss increased 50% to $139.9M. Higher net loss reflects Research and Development - Balancing val increase of 52% to $105.3M (expense), General and administrative - Balancing v increase of 56% to $24.1M (expense), Stock-based Compensation in SGA increase of 52% to $7.9M (expense).
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -47.83 | -47.08 | -51.83 | -37.6 |
Net Income | -45.74 | -44.76 | -49.39 | -35.59 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 441.51 | 478.11 | 455.18 | 472.56 |
Total Liabilities | 58.05 | 58.41 | 53.18 | 29.8 |
Total Equity | 383.46 | 419.7 | 402 | 442.75 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 0 Months | 0 Months |
Cash From Operating Activities | -118.92 | -83.04 | -42.22 | -107.98 |
Cash From Investing Activities | -24.77 | -13 | 28.03 | -185.05 |
Cash From Financing Activities | 62.93 | 50.69 | 3 | 398.46 |
Net Change in Cash | -80.76 | -45.35 | -11.19 | 105.44 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review